Last reviewed · How we verify
Zyprexa
At a glance
| Generic name | Zyprexa |
|---|---|
| Sponsor | Washington University School of Medicine |
| Target | Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Agitation associated with Bipolar Mania
- Agitation associated with Schizophrenia
- Bipolar affective disorder, current episode depression
- Bipolar affective disorder, current episode manic
- Bipolar disorder in remission
- Depression Treatment Adjunct
- Major depressive disorder
- Mixed bipolar I disorder
- Schizophrenia
Common side effects
Key clinical trials
- An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC (PHASE4)
- A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia (PHASE3)
- Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile (PHASE2)
- Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients (PHASE3)
- Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting (PHASE3)
- A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and Palonosetron (NA)
- An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (PHASE4)
- Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |